Policy & Advocacy   |   Policy Summit

FDA's Dr. Nicole Verdun and Julie Tierney to Speak at ASGCT's 2024 Policy Summit

May 29, 2024

Register today to take advantage of this chance to hear from two influential FDA officials on key cell and gene therapy policy issues at the ASGCT Policy Summit this September.

The American Society of Gene and Cell Therapy (ASGCT) is excited to announce that two top officials from the U.S. Food and Drug Administration (FDA) will be featured speakers at the upcoming 2024 Policy Summit on September 23-24 at the Westin Washington DC Downtown Hotel.

Nicole Verdun, MD, Super Office Director for the Office of Therapeutic Products at FDA's Center for Biologics Evaluation and Research (CBER), will participate in a panel discussion on Global Regulatory Convergence. She will be joined by other regulatory leaders from around the world to discuss international collaborations, pilots, benefits and challenges of harmonization efforts, regulatory considerations for accelerated approval pathways, and more.

Julie Tierney, Deputy Center Director for Strategy, Policy, and Legislation at CBER, will take part in a one-on-one Fireside Chat moderated by Kristin Van Goor, PhD. Tierney will dive into key issues such as implementation of the upcoming PDUFA VII, CBER's pilot programs, the regulatory guidance landscape, how FDA is responding to emerging science and trends in cell and gene therapy, and her unique perspective from her previous role in the FDA Commissioner's office.

Don't miss this chance to hear directly from two of the FDA's most prominent voices shaping the regulatory landscape for cell and gene therapies. The Policy Summit connects you with thought leaders across the field to discuss critical regulatory, legislative and payment issues impacting therapy development.

Register Today for the Policy Summit

Register now to attend in person at the Westin Washington DC Downtown Hotel or virtually. Both options include access to on-demand content for 30 days after the event. In-person registration is limited, so secure your spot early.

Shape the future of cell and gene therapy by joining ASGCT's advocacy community. Subscribe to The Advocate newsletter to stay informed on the Society's policy and advocacy initiatives.

Related Articles

Maria Santaella, PhD (c), MSN, RN-BC, CPHON serves as the Vice President of Research for the National Bleeding Disorders Foundation. During the workshop she spoke on clinical trial enrollment by sharing strategies to address barriers in recruiting.

Annual Meeting 2024

Inclusive Trial Design Amplifies Patient Voices and Drives Meaningful Outcomes

Samuel Hughes, MBA, St. Jude Children's Research Hospital - June 18, 2024
Annual Meeting 2024

Patient Advocates Connect at the Annual Meeting

Ali Kujawski, Senior Patient Outreach Manager - June 12, 2024
Policy & Advocacy

ASGCT Urges Congress to Address Gene Therapy Access Hurdles

Margarita Valdez Martínez - May 24, 2024
Policy & Advocacy

FDA Hosts Third Installment of CGT Science Series on CMC Guidance

Watch now! - April 11, 2024